Professor, Departments of Medicine and Oncology, McGill University
Director, Department of Oncology, McGill University
Director, McGill Centre for Translational Research in Cancer
Lady Davis Institute for Medical Research
Sir Mortimer B. Davis-Jewish General Hospital
3755 Côte Ste-Catherine Road
Montreal, Quebec H3T 1E2
Tel.: 514-340-8222 ext. 5418
gbatist [at] onc [dot] jgh [dot] mcgill [dot] ca (Email)
Expertise: Suicide Gene Therapy; Environmental Carcinogens; Preclinical Studies
Summary of Research Activities
Dr Gerald Batist is Chairman of the Department of Oncology, McGill University. He is also director of the McGill Centre for Translational Research in Cancer which is a comprehensive cancer research and treatment program that includes a Clinical Research Unit, Tissue Repository, a molecular modeling unit, a GMP cell preparation facility and virtual link-up of scientists throughout Montreal focusing on laboratory-clinic interface research.
A Professor in the Departments of Medicine and Oncology at McGill University, Dr Batist is also an associate member of the Department of Pharmacology & Therapeutics, the McGill Cancer Centre and the Experimental Medicine Division in the Department of Medicine. He is also an associate member of the Department of Pharmacology at the Université de Montréal.
He is the author of over 100 scientific publications and has been invited to give presentations at national and international conferences.
Recently, the Canadian Foundation for Innovation awarded support for the construction of the new Montreal Centre for Experimental Therapeutics in Cancer directed by Dr Batist. This new Centre brings together senior scientists from most Montreal universities and research institutes, as well as colleagues from Sherbrooke and Quebec City. The Centre builds on the progress of the Translational Research Centre in developing collaborative research in novel therapeutics in cancer treatment and prevention.
Dr. Batist’s research focuses on three themes: 1) suicide gene therapy in cancer, particularly regarding tumor-specific promoter systems and on amplifying the “bystander effect” by modulating gap junctions. 2) Biochemical modulation of cellular detoxification systems, including glutathione and related enzymes. This ranges from potentials in both anticancer research and environmental carcinogenesis. 3) Preclinical studies of a range of novel therapeutics and laboratory support of early phase clinical trials.
Hamilton D, Loignon M, Alaoui-Jamali MA, Batist G. Novel use of the fluorescent dye 5-(and-6)-chloromethyl SNARF-1 acetate for the measurement of intracellular glutathione in leukemic cells and primary lymphocytes. Cytometry A. 2007 Sep;71(9):709-15.
Hamilton D, Wu JH, Batist G. Structure-based identification of novel human gamma-glutamylcysteine synthetase inhibitors. Mol Pharmacol. 2007 Apr; 71(4): 1140-7. Epub 2007 Jan 17.
Cohen V, Agulnik JS, Jarry J, Batist G, Small D, Kreisman H, Adriana Tejada N, Miller WH Jr, Chong G. Related Articles, Links Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer. Cancer. 2006 Dec 15;107(12):2858-65.
Mes-Masson AM, Champoux L, Hebert J, Batist G, Lesperance B. [The reseau de recherche sur le cancer: favoring a multi-disciplinary approach] Bull Cancer. 2006 Sep 1;93(9):831-4.
Batist G, Harris L, Azarnia N, Lee LW, Daza-Ramirez P. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anticancer Drugs. 2006 Jun;17(5):587-95.
Hernandez M, Shao Q, Yang XJ, Luh SP, Kandouz M, Batist G, Laird DW, Alaoui-Jamali MA. A histone deacetylation-dependent mechanism for transcriptional repression of the gap junction gene cx43 in prostate cancer cells. Prostate. 2006 Aug 1;66(11):1151-61.
Haidara K, Zamir L, Shi QW, Batist G. The flavonoid Casticin has multiple mechanisms of tumor cytotoxicity action. Cancer Lett. 2006 Oct 28; 242(2): 180-90. Epub 2006 Jan 4.